Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/05/07/2876665/0/en/Cogent-Biosciences-Reports-First-Quarter-2024-Financial-Results.html
https://www.globenewswire.com/news-release/2024/04/09/2860059/0/en/Cogent-Biosciences-Presents-Data-Highlighting-Potential-Best-in-Class-Potency-and-Selectivity-of-Novel-EGFR-Sparing-CNS-Penetrant-ErbB2-Inhibitor.html
https://www.globenewswire.com//news-release/2024/02/26/2835100/0/en/Cogent-Biosciences-Reports-Recent-Business-Highlights-and-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html
https://www.globenewswire.com//news-release/2024/02/22/2834028/0/en/Cogent-Biosciences-Announces-Positive-Part-1b-Data-from-SUMMIT-Trial-Evaluating-Bezuclastinib-in-Patients-with-Nonadvanced-Systemic-Mastocytosis.html
https://www.globenewswire.com//news-release/2024/02/14/2828971/0/en/Cogent-Biosciences-Announces-Oversubscribed-225-Million-Private-Placement.html
https://www.globenewswire.com//news-release/2024/02/05/2823572/0/en/Cogent-Biosciences-to-Present-SUMMIT-Part-1b-Data-with-Bezuclastinib-in-NonAdvanced-Systemic-Mastocytosis-NonAdvSM-at-the-2024-AAAAI-Annual-Meeting.html
https://www.globenewswire.com//news-release/2024/01/09/2806211/0/en/Cogent-Biosciences-Announces-Planned-2024-Milestones-for-Bezuclastinib-and-Emerging-Portfolio-of-Selective-and-Potent-Targeted-Therapeutics.html
https://www.globenewswire.com//news-release/2024/01/02/2802625/0/en/Cogent-Biosciences-Announces-Presentation-at-the-42nd-Annual-J-P-Morgan-Healthcare-Conference.html
https://www.globenewswire.com//news-release/2023/12/11/2793781/0/en/Cogent-Biosciences-Announces-Positive-Data-from-Ongoing-Phase-2-APEX-Trial-Evaluating-Bezuclastinib-in-Patients-with-Advanced-Systemic-Mastocytosis-AdvSM.html
https://www.globenewswire.com//news-release/2023/12/09/2793443/0/en/Cogent-Biosciences-Announces-Positive-Initial-Data-from-Phase-2-SUMMIT-Trial-Evaluating-Bezuclastinib-in-Patients-with-Nonadvanced-Systemic-Mastocytosis-NonAdvSM.html